Scarica l'app Stockscreener
27.73
2.23%
-0.465
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Agios Pharmaceuticals (AGIO) Target Price Raised by Citi - GuruFocus
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors o - GuruFocus
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets - Yahoo Finance
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO (2026-03-04) - Seeking Alpha
Agios Pharmaceuticals, Inc. $AGIO Shares Sold by TD Asset Management Inc - MarketBeat
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact The Gross Law Firm Regarding Potential Securities Law ViolationsAGIO - StreetInsider
Agios (AGIO) CMO logs tax-driven share sales and major new equity awards - Stock Titan
Agios (NASDAQ: AGIO) CEO Brian Goff receives large equity grants, sells shares for tax withholding - Stock Titan
AGIOS (AGIO) legal chief gains RSUs, options and sells shares for taxes - Stock Titan
Agios Pharmaceuticals (AGIO) CFO equity grants and tax-driven sales - Stock Titan
AGIOS (NASDAQ: AGIO) CCO reports new equity awards and tax-driven share sales - Stock Titan
Agios (AGIO) accounting officer sells shares to cover RSU tax withholding - Stock Titan
Agios (NASDAQ: AGIO) executive granted 14,000 RSUs and 52,000 options - Stock Titan
AGIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights A - GuruFocus
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction - MarketBeat
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
AGIO (Nasdaq: AGIO) reports RSU vesting and Brian Goff sale disclosure - Stock Titan
AGIO (NASDAQ: AGIO) insider resale notice for 5,218 shares on 03/02/2026 - Stock Titan
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Insider sale notice: 5,035 AGIO shares tied to RSU vesting (NASDAQ: AGIO) - Stock Titan
Insider sells and RSUs vest at AGIO (NASDAQ: AGIO) — 2,868 RSUs listed - Stock Titan
AGIO: Mitapivat’s thalassemia launch accelerates, with pipeline and regulatory catalysts ahead - TradingView
Agios' Pyrukynd® (mitapivat) approved for adults with thalassemia in the United Arab Emirates - marketscreener.com
Agios Pharmaceuticals (AGIO) Gains UAE Approval for Pyrukynd - GuruFocus
Vanguard Group Inc. Sells 77,143 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - Bitget
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - The Manila Times
UAE approves only treatment option for adults with thalassemia - Stock Titan
Agios Pharmaceuticals Q3 Loss Of US$103.4m Reinforces Bearish Profitability Narratives - Sahm
Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Passes Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: A 28.73% Upside Potential Amidst Strong Revenue Growth - DirectorsTalk Interviews
Understanding Momentum Shifts in (AGIO) - Stock Traders Daily
Agios Pharmaceuticals (AGIO) reports Q4 loss, beats revenue estimates - MSN
BOOTHBAY FUND MANAGEMENT, LLC's Agios Pharmaceuticals Inc(AGIO) Holding History - GuruFocus
Eagle Health Investments LP Sells 84,600 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Why Agios Pharmaceuticals Inc. stock is popular among millennialsTrade Volume Summary & High Yield Stock Recommendations - mfd.ru
Alpha Thalassemia Market to Reach US$ 1.9 Billion by 2031 | North - openPR.com
Agios’ 2025 Loss, AQVESME Launch, and New Shelf Offering Might Change The Case For Investing In Agios Pharmaceuticals (AGIO) - Sahm
HC Wainwright Issues Positive Estimate for AGIO Earnings - MarketBeat
Is Agios Pharmaceuticals Inc. stock overvalued by current metricsLayoff News & Smart Swing Trading Alerts - mfd.ru
RBC Capital Sticks to Their Hold Rating for Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress - Yahoo Finance
Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook - The Globe and Mail
Wall Street Zen Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold - MarketBeat
Agios Pharmaceuticals Q4 2025 earnings preview - MSN
STATE STREET CORP Acquires Additional Shares in Agios Pharmaceuticals Inc - GuruFocus
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Brokers Offer Predictions for AGIO FY2030 Earnings - MarketBeat
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Q4 2025 slides: PYRUKYND revenue surges 86%, thalassemia launch underway - Investing.com Canada
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insight - GuruFocus
Agios Pharmaceuticals (AGIO) Files Automatic Mixed Securities Shelf - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlight - GuruFocus
Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Does Agios Pharmaceuticals Inc. have a competitive edgeRate Cut & Smart Swing Trading Techniques - mfd.ru
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):